文献速递浆细胞疾病

髓外播散时机与模式是多发性骨髓瘤生存的关键决定因素

Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple Myeloma.
PubMed 文献 · Am J Hematol · 2026-05-14

该研究纳入543例纵向随访的多发性骨髓瘤患者,用全身影像(WB-MRI±FDG-PET/CT)刻画髓外病变,并将髓外状态作为时变协变量纳入多变量Cox模型。结果显示髓外病变见于24.6%病例,且按播散时机与模式呈现预后分层:诊断时原发椎旁病变HR=2.22,继发椎旁病变HR=3.33,继发髓外病变HR=8.14。病变体积和解剖位置无预后价值,而继发髓外病变、R2-ISS IV期、治疗线数和TP53突变独立预测髓外诊断后生存。

要点

  • 髓外病变按播散时机与模式分层预后,继发髓外病变风险最高(HR=8.14)。
  • 初始椎旁病变进展为继发髓外病变的风险增加2.6倍(p=0.002)。
  • 病变体积和解剖位置无预后价值,应将时机与空间特征纳入风险模型。

核心结论

  • 髓外受累定义侵袭性表型,预后由播散时机和模式而非肿瘤负荷驱动。
  • 髓外病变的不良影响在调整R2-ISS和细胞遗传学后仍持续存在。

研究设计与样本

  • 回顾性队列研究,纳入543例2010至2025年纵向随访的多发性骨髓瘤患者。
  • 使用全身影像包括WB-MRI±FDG-PET/CT刻画髓外病变。
  • 将髓外状态作为时变协变量纳入多变量Cox比例风险模型评估总生存。

主要发现

  • 髓外病变见于24.6%病例(n=134)。
  • 与骨髓局限病变相比,诊断时原发椎旁病变HR=2.22,继发椎旁病变HR=3.33,继发髓外病变HR=8.14。
  • 初始椎旁病变患者进展为继发髓外病变的风险增加2.6倍(p=0.002)。
  • 继发髓外病变、R2-ISS IV期、治疗线数和髓外诊断时TP53突变独立预测髓外诊断后生存降低。
  • 病变体积和解剖位置无预后价值。

临床怎么用

  • 全身影像可准确识别向高危组别转变的患者。
  • 未来风险框架应整合髓外播散的时机与空间特征以改善预后判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Extraosseous (EO) involvement in multiple myeloma (MM) is a critical marker of systemic clonal escape, but its spatial and temporal dynamics are largely omitted from current risk models like R2-ISS. In this cohort of 543 patients with longitudinal follow-up between 2010 and 2025, whole-body (WB) imaging including WB-MRI ± FDG-PET/CT was used to characterize EO disease. EO status was modeled as a time-varying covariate in multivariable Cox proportional hazards models including clinical, biological, and genetic covariates to assess impact on overall survival (OS). EO disease was identified in 24.6% of cases (n = 134). We identified a distinct prognostic hierarchy for OS based on the timing and pattern of dissemination: compared to marrow-confined disease, prognosis was increasingly worse for primary paraskeletal (PS) lesions present at diagnosis (HR = 2.22), secondary PS (HR = 3.33), and reaching an ultra-high-risk for secondary extramedullary disease (EMD) (HR = 8.14). Patients with initial PS lesions faced a 2.6-fold increased risk of evolving into secondary EMD (p = 0.002). While lesion volume and anatomical localization of EO lacked prognostic value, secondary EMD, R2-ISS stage IV, number of lines of treatment and TP53 mutation at time of EO diagnosis independently predicted lower post-EO survival. Thus, EO involvement defines an aggressive phenotype in which prognosis is driven by the timing and dissemination pattern rather than EO tumor burden. WB imaging accurately identifies patients transitioning into these high-risk groups. Integrating timing and spatial EO features into future risk frameworks is essential for better prognostication, as the adverse impact of EO disease persists even after adjusting for R2-ISS and cytogenetic status.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Tordjman M, Meribout A, Geahchan A, et al. Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple Myeloma. Am J Hematol. 2026. PMID: 42132247. doi:10.1002/ajh.70370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。